TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cuttings in connection with the 51st Annual General Meeting and E-Voting Procedure.01-07-2024
01-07-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Submission Of The Annual Report For The FY 2023-24 And The Notice Convening 51St Annual General Meeting Of The Company.
Submission of the Annual Report for the FY 2023-24 and the Notice convening 51st AGM of the Company29-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Business Responsibility and Sustainability Reporting (BRSR)
Submission of the Business Responsibility and Sustainability Report (BRSR) for FY 2023-24 of the Company29-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Reg. 34 (1) Annual Report.
Submission of Annual Report for FY 2023-24 and intimation of voting through electronic means29-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window
Intimation of the Closure of Trading Window as per Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons28-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Intimation of the 51st Annual General Meeting of the Company through Video Conferencing / Other Audio Visual Means ("VC / OAVM") facility25-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201521-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates19-06-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate13-06-2024
Torrent Pharma slips 3% after USFDA issues 5 observations for Indrad Unit
The fall came after the United States Food and Drug Administration (USFDA) issued a Form 483 with five observations for the Indrad unit13-06-2024